The first project will support hypertension research in Abu Dhabi in partnership with UAE-based healthcare firm M42
Reuters
20 October, 2026, 02:45 pm
Last modified: 20 October, 2026, 02:54 pm
AstraZeneca's collaboration with Oracle will combine the drugmaker's expertise in drug development with Oracle's AI and healthcare data capabilities to support patient matching and research.
Initial work will focus on cancer, cardiovascular, respiratory, immunology and rare diseases, and could also support earlier diagnosis of serious diseases.
The first project will support hypertension research in Abu Dhabi in partnership with UAE-based healthcare firm M42.
Patient recruitment remains one of the biggest challenges in clinical research, with delayed enrolment often extending trial timelines and increasing development costs.
Incorrect trial designs have also hurt AstraZeneca in the past, with delays involving its breast cancer drug and nerve disorder treatment failure causing some concerns.
AstraZeneca is seeking to expand its medicine portfolio as it targets more than $80 billion in annual revenue by 2030 and works to address industry bottlenecks in drug development.